Literature DB >> 17346928

Interleukin-17F signaling requires ubiquitination of interleukin-17 receptor via TRAF6.

Zhili Rong1, Long Cheng, Yongming Ren, Zhiyong Li, Yinghua Li, Xueni Li, Hongge Li, Xin-Yuan Fu, Zhijie Chang.   

Abstract

Interleukin-17F (IL-17F), together with interleukin-17A (IL-17 or IL-17A), is a marker of T(H)17 cells, a new lineage of effector CD4(+) T cells to contribute to pathogenesis of a growing list of autoimmune and inflammatory diseases, such as experimental autoimmune encephalitis (EAE) and collagen-induced arthritis (CIA). IL-17F, similar to IL-17A, was reported to employ interleukin-17 receptor (IL-17R or IL-17RA) for signaling but the downstream cascades remain largely elusive. Here we report that TRAF6 interacts with IL-17R and mediates ubiquitination of the receptor. We observed that IL-17F and IL-17A could induce IL-17R ubiquitination and DN-TRAF6, a dominant-negative mutant, could block IL-17F- but not IL-17A-triggered ubiquitination of IL-17R. Moreover, we showed that the ubiquitination of IL-17R was positively correlated with the downstream signaling, as evaluated by a luciferase reporter driven by a putative native promoter of 24p3, an IL-17 targeted gene. Our results indicate that ubiquitination of IL-17R mediated by TRAF6 plays a critical role in IL-17F signaling. This study, for the first time, reveals a possible molecular mechanism that the initiation of the IL-17F/IL-17R signaling pathway requires the receptor ubiquitination by TRAF6.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17346928     DOI: 10.1016/j.cellsig.2007.01.025

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  20 in total

1.  F-box protein FBXL19-mediated ubiquitination and degradation of the receptor for IL-33 limits pulmonary inflammation.

Authors:  Jing Zhao; Jianxin Wei; Rachel K Mialki; Daniel F Mallampalli; Bill B Chen; Tiffany Coon; Chunbin Zou; Rama K Mallampalli; Yutong Zhao
Journal:  Nat Immunol       Date:  2012-06-03       Impact factor: 25.606

Review 2.  Structure-function relationships in the IL-17 receptor: implications for signal transduction and therapy.

Authors:  Fang Shen; Sarah L Gaffen
Journal:  Cytokine       Date:  2008-01-04       Impact factor: 3.861

Review 3.  TRAF6 activation in multiple myeloma: a potential therapeutic target.

Authors:  Hong Liu; Samantha Tamashiro; Stavroula Baritaki; Manuel Penichet; Youhua Yu; Haiming Chen; James Berenson; Benjamin Bonavida
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2012-03-21

Review 4.  IL-17F: regulation, signaling and function in inflammation.

Authors:  Seon Hee Chang; Chen Dong
Journal:  Cytokine       Date:  2009-02-23       Impact factor: 3.861

5.  IL-17RD (Sef or IL-17RLM) interacts with IL-17 receptor and mediates IL-17 signaling.

Authors:  Zhili Rong; Anan Wang; Zhiyong Li; Yongming Ren; Long Cheng; Yinghua Li; Yinyin Wang; Fangli Ren; Xiaoning Zhang; Jim Hu; Zhijie Chang
Journal:  Cell Res       Date:  2009-02       Impact factor: 25.617

Review 6.  Regulatory mechanisms of helper T cell differentiation: new lessons learned from interleukin 17 family cytokines.

Authors:  Bhanu P Pappu; Pornpimon Angkasekwinai; Chen Dong
Journal:  Pharmacol Ther       Date:  2008-01-19       Impact factor: 12.310

7.  Tumor necrosis factor receptor-associated factor 6 is an intranuclear transcriptional coactivator in osteoclasts.

Authors:  Shuting Bai; Jikun Zha; Haibo Zhao; F Patrick Ross; Steven L Teitelbaum
Journal:  J Biol Chem       Date:  2008-09-03       Impact factor: 5.157

Review 8.  Barrier immunity and IL-17.

Authors:  Benjamin R Marks; Joe Craft
Journal:  Semin Immunol       Date:  2009-04-21       Impact factor: 11.130

Review 9.  Structure and signalling in the IL-17 receptor family.

Authors:  Sarah L Gaffen
Journal:  Nat Rev Immunol       Date:  2009-07-03       Impact factor: 53.106

10.  IL-17A inhibits the expansion of IL-17A-producing T cells in mice through "short-loop" inhibition via IL-17 receptor.

Authors:  Emily Smith; Matthew A Stark; Alexander Zarbock; Tracy L Burcin; Anthony C Bruce; Devin Vaswani; Patricia Foley; Klaus Ley
Journal:  J Immunol       Date:  2008-07-15       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.